PGNX Progenics Pharmaceuticals Inc.

7.89
+0  (2%)
Previous Close 7.70
Open 7.76
Price To book 5.16
Market Cap 553.80M
Shares 70,190,000
Volume 1,075,007
Short Ratio 4.17
Av. Daily Volume 1,441,170

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 initiation announced December 7, 2016.
PyL
Prostate cancer
Pivotal Phase 2 trial resumed January 2015 following suspension of trial in 2010 due to lack of funding. Primary endpoint met - March 30, 2017. NDA filing due mid-2017.
Azedra
Pheochromocytoma
Phase 3 interim analysis completed December 22, 2016 by Data Monitoring Committee (DMC). Trial to continue.
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Approved July 19 2016.
Oral RELISTOR
Chronic pain
Approved September 29, 2014.
Subcutaneous RELISTOR
Chronic pain
Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.
PSMA ADC
Cancer - metastatic castrate resistant prostate cancer (mCRPC).

Latest News

  1. ETFs with exposure to Progenics Pharmaceuticals, Inc. : April 25, 2017
  2. Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
  3. What Poker Taught Me About Investing
  4. Progenics Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
  5. Progenics Azedra Succeeds in Mid-Stage Trials
  6. Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA®
  7. Data from Phase 2 Study of Progenics’ PSMA-Targeted Imaging Agent 1404 Published in Journal of Nuclear Medicine
  8. Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
  9. Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  10. Progenics reports 4Q loss
  11. Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update
  12. Progenics Pharmaceuticals (PGNX) in Focus: Stock Gains 8.3%
  13. Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial Results Call for March 9
  14. Biotech Premarket Movers: Progenics, Alexion, BioCryst
  15. Progenics Pharmaceuticals and Shutterfly to Join S&P SmallCap 600
  16. Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted Therapeutic Candidate 1095 For the Treatment of Metastatic Prostate Cancer
  17. Progenics Pharmaceuticals, Inc. to Participate in February Investor Conferences
  18. Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : January 30, 2017
  19. Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PGNX-US : January 27, 2017
  20. ETFs with exposure to Progenics Pharmaceuticals, Inc. : January 20, 2017